Predicting nodal response to neoadjuvant treatment in breast cancer with core biopsy biomarkers of tumor microenvironment using data mining.

IF 3 3区医学 Q2 ONCOLOGY Breast Cancer Research and Treatment Pub Date : 2024-11-04 DOI:10.1007/s10549-024-07539-9

Nina Pislar, Gorana Gasljevic, Erika Matos, Gasper Pilko, Janez Zgajnar, Andraz Perhavec

{"title":"Predicting nodal response to neoadjuvant treatment in breast cancer with core biopsy biomarkers of tumor microenvironment using data mining.","authors":"Nina Pislar, Gorana Gasljevic, Erika Matos, Gasper Pilko, Janez Zgajnar, Andraz Perhavec","doi":"10.1007/s10549-024-07539-9","DOIUrl":null,"url":null,"abstract":"Purpose: To generate a model for predicting nodal response to neoadjuvant systemic treatment (NAST) in biopsy-proven node-positive breast cancer patients (cN+) that incorporates tumor microenvironment (TME) characteristics and could be used for planning the axillary surgical staging procedure.Methods: Clinical and pathologic features were retrospectively collected for 437 patients. Core biopsy (CB) samples were reviewed for stromal content and tumor-infiltrating lymphocytes (TIL). Orange Datamining Toolbox was used for model generation and assessment.Results: 151/437 (34.6%) patients achieved nodal pCR (ypN0). The following 5 variables were included in the prediction model: ER, Her-2, grade, stroma content and TILs. After stratified tenfold cross-validation, the logistic regression algorithm achieved and area under the ROC curve (AUC) of 0.86 and F1 score of 0.72. Nomogram was used for visualization.Conclusions: We developed a clinical tool to predict nodal pCR for cN+ patients after NAST that includes biomarkers of TME and achieves an AUC of 0.86 after tenfold cross-validation.","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-024-07539-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To generate a model for predicting nodal response to neoadjuvant systemic treatment (NAST) in biopsy-proven node-positive breast cancer patients (cN+) that incorporates tumor microenvironment (TME) characteristics and could be used for planning the axillary surgical staging procedure.

Methods: Clinical and pathologic features were retrospectively collected for 437 patients. Core biopsy (CB) samples were reviewed for stromal content and tumor-infiltrating lymphocytes (TIL). Orange Datamining Toolbox was used for model generation and assessment.

Results: 151/437 (34.6%) patients achieved nodal pCR (ypN0). The following 5 variables were included in the prediction model: ER, Her-2, grade, stroma content and TILs. After stratified tenfold cross-validation, the logistic regression algorithm achieved and area under the ROC curve (AUC) of 0.86 and F1 score of 0.72. Nomogram was used for visualization.

Conclusions: We developed a clinical tool to predict nodal pCR for cN+ patients after NAST that includes biomarkers of TME and achieves an AUC of 0.86 after tenfold cross-validation.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

利用数据挖掘的肿瘤微环境核心生物标志物预测乳腺癌新辅助治疗的结节反应。

目的：建立一个模型，用于预测活检证实的结节阳性乳腺癌患者（cN+）对新辅助系统治疗（NAST）的结节反应，该模型结合了肿瘤微环境（TME）特征，可用于规划腋窝手术分期程序：方法：回顾性收集了 437 例患者的临床和病理特征。对核心活检（CB）样本的基质含量和肿瘤浸润淋巴细胞（TIL）进行了审查。使用橙色数据挖掘工具箱生成模型并进行评估：151/437（34.6%）例患者达到结节 pCR（ypN0）。预测模型包括以下 5 个变量：ER、Her-2、分级、基质含量和TIL。经过分层十倍交叉验证后，逻辑回归算法的 ROC 曲线下面积（AUC）为 0.86，F1 得分为 0.72。结论：我们开发了一种预测结节的临床工具：我们开发了一种临床工具，用于预测NAST术后cN+患者的结节pCR，其中包括TME的生物标记物，经过十倍交叉验证后，AUC达到0.86。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Breast Cancer Research and Treatment 医学-肿瘤学

CiteScore

6.80

自引率

2.60%

发文量

342

审稿时长

1 months

期刊介绍： Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.